Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Shiyu Capital

Founders Calvin Cao Hongbing Yang

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 18
Average round size
info
The average size of a deal this fund participated in
$73M
Portfolio companies 15
Rounds per year 1.80
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Pharmaceutical
  • Medical
  • Therapeutics
Summary

Shiyu Capital is the famous VC, which was founded in 2014. The main department of described VC is located in the Beijing. The venture was found in Asia in China.

The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Shiyu Capital, startups are often financed by Stone Capital, H&Q Asia Pacific. The meaningful sponsors for the fund in investment in the same round are Legend Capital, Zhuhai Huajin Asset, State Development & Investment Corporation (SDIC).

We can highlight the next thriving fund investment areas, such as Medical, Health Care. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Biotheus. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund.

The current fund was established by Calvin Cao, Hongbing Yang. Besides them, we counted 2 critical employees of this fund in our database.

The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. Considering the real fund results, this VC is 37 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from Shiyu Capital is 500 millions - 1 billion dollars. The top activity for fund was in 2019.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Shiyu Capital:
Typical Co-investors
Shiyu Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Shiyu Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Brasil Venture Debt Brazil, São Paulo, Sao Paulo
Clark Ventures Atlanta, Georgia, United States
Dentsu Ventures Chiyoda, Japan
DIA Investments -
DM Wellness -
Eyrir Invest Gullbringusysla, Iceland, Reykjavík
Gainsight California, San Francisco, United States
Heads or Tails Investments -
i-nest capital Japan, Tokyo
Lacomp Plc -
Night Media Dallas, Texas, United States
P. Schoenfeld Asset Management New York, New York, United States
PRD Angels -
Primus Capital Partners Cleveland, Ohio, United States
Shanxi Wenhua Zichan China, Shaanxi, Xian Shi
Shengtai Xinli Beijing, Beijing, China
Technorov Holdings -
USC Marshall Venture Fund California, Los Angeles, United States
V-Guard Industries India, Kerala, Kochi
Zech Group -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Hainan Zhongle

$773K28 Feb 2024 Haikou, Hainan, China

Health Care
Pharmaceutical
$20M31 Mar 2021 Shanghai, China

Biotheus

Biotechnology
Health Care
03 Mar 2021 Xiangzhou District, Guangdong Province, China

Health Diagnostics
Medical
Medical Device
$150M23 Feb 2021 Shanghai, China

CARsgen Therapeutics

Health Diagnostics
Medical
Therapeutics
$186M02 Nov 2020 Shanghai, China

Biopharma
Biotechnology
Life Science
$278M29 Apr 2020 China, Shanghai

Lepu Bio

Biotechnology
Health Care
$139M02 Jul 2019 Shanghai, China

Biotheus

Biotechnology
Health Care
$15M26 Jun 2019 Xiangzhou District, Guangdong Province

Allist Pharmaceuticals

Pharmaceutical
$185M24 May 2019 China, Shanghai
News
OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing

– OnQuality Pharmaceuticals LLC (“OnQuality”), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced the closing of its Series A+ financing round securing an additional $20 million in funding. This brings the total amount of capital raised in Series A and A+ to $35 million.
– This financing round included participation from Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, FreeS Fund, and additional biotech veterans.
– Proceeds from the financing will support the ongoing Phase II clinical trial of the company’s leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
OnQuality also announced the appointment of pharmaceutical executive Michael McCullar, Ph.

WuXi Diagnostics Secures US$150 Million Series B Financing to Accelerate Market Penetration in Global Diagnostics Sector

– WuXi Diagnostics secured a US$150m Series B financing round to accelerate market penetration in the global diagnostics sector.
– The round was joined by new investors including Thermo Fisher, Shiyu Capital, ABC International, Sunland Capital, and CCBI Tech Venture.
– WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.
– WuXi Diagnostics is the first platform company in China focusing on integrated diagnostics. Since its establishment in 2018, WuXi Diagnostics has continuously promoted the clinical practice of integrated diagnostics by virtue of its open-access innovation enabling platform, centered on multi-omics clinical data from multidisciplinary technologies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Shiyu Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 18
Average round size 73M
Rounds per year 1.80
Peak activity year 2019
Lead investments 7
Follow on index 0.11
Group Appearance index 0.94

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Hainan Zhongle

$773K28 Feb 2024 Haikou, Hainan, China

Health Care
Pharmaceutical
$20M31 Mar 2021 Shanghai, China

Biotheus

Biotechnology
Health Care
03 Mar 2021 Xiangzhou District, Guangdong Province, China

Health Diagnostics
Medical
Medical Device
$150M23 Feb 2021 Shanghai, China

CARsgen Therapeutics

Health Diagnostics
Medical
Therapeutics
$186M02 Nov 2020 Shanghai, China

Biopharma
Biotechnology
Life Science
$278M29 Apr 2020 China, Shanghai

Lepu Bio

Biotechnology
Health Care
$139M02 Jul 2019 Shanghai, China

Biotheus

Biotechnology
Health Care
$15M26 Jun 2019 Xiangzhou District, Guangdong Province

Allist Pharmaceuticals

Pharmaceutical
$185M24 May 2019 China, Shanghai
Crunchbase icon

Content report

The following text will be sent to our editors: